AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12182381 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II and VARIVAX given concomitantly at separate sites (Group A)
Number of subjects: 603
Study 12182381 — intervention group
Group type: COMPARATOR
Intervention: M-M-R II and VARIVAX administered 6 weeks apart (Group B)
Number of subjects: 603
Study 12182381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 603
Study 10622297 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with LCPUFAs
Number of subjects: 447
Study 10622297 — intervention group
Group type: COMPARATOR
Intervention: Formula without LCPUFAs
Number of subjects: 447
Study 10622297 — intervention group
Group type: COMPARATOR
Intervention: Breastfed reference group
Number of subjects: 447
Study 8575573 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 200 micrograms b.i.d. for 3 months
Number of subjects: 27
Study 8575573 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. for 3 months
Number of subjects: 27
Study 1827588 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 10
Study 1827588 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 10
Study 375881 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine treatment (250 mg, 3 capsules per day)
Number of subjects: 11
Study 375881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose, 3 capsules per day)
Number of subjects: 11
Study 28633675 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiao's scalp acupuncture combined with conventional rehabilitation treatment
Number of subjects: 108
Study 28633675 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment
Number of subjects: 108
Study 26426042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intramuscular phylloquinone
Number of subjects: 0
Study 26426042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intramuscular phylloquinone
Number of subjects: 0
Study 26426042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intravenous phylloquinone
Number of subjects: 0
Study 26426042 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 0
Study 26426042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of phylloquinone at birth
Number of subjects: 0
Study 23110811 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CT) with epirubicin 120 mg/m² and ifosfamide 9 g/m² followed by two postoperative cycles
Number of subjects: 252
Study 23110811 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (CT) with radiotherapy (RT)
Number of subjects: 252
Study 23110811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preoperative CT-RT in patients with positive surgical margins
Number of subjects: 252
Study 20963831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (112 mg, twice daily)
Number of subjects: 95
Study 20963831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder
Number of subjects: 95
Study 20963831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 19197779 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based course on cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 19197779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype module of the Web-based course
Number of subjects: 0
Study 16961166 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70
Study 16961166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 70
Study 15589109 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of galantamine (GAL)
Number of subjects: 28
Study 15589109 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no galantamine)
Number of subjects: 28
Study 11064501 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy (two nucleoside reverse transcriptase inhibitors (NRTIs) plus one protease inhibitor)
Number of subjects: 94
Study 11064501 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (two NRTIs)
Number of subjects: 94
Study 11064501 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy
Number of subjects: 94
Study 11064501 — intervention group
Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 94
Study 11064501 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 94
Study 11064501 — intervention group
Group type: COMPARATOR
Intervention: Double therapy and Triple therapy
Number of subjects: 94
Study 9308583 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (n = 56)
Number of subjects: 115
Study 9308583 — intervention group
Group type: COMPARATOR
Intervention: Endovascular management (n = 59)
Number of subjects: 115
Study 8144850 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant in early follicular phase)
Number of subjects: 18
Study 8144850 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant in late luteal phase)
Number of subjects: 18
Study 8144850 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot formulation 3.6 mg every 28 days for 6 months (first implant on 3rd and 17th day from onset of menses)
Number of subjects: 18
Study 3530442 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 88
Study 3530442 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study 29976078 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg multi-strain probiotic (MS)
Number of subjects: 300
Study 29976078 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg single-strain probiotic (SS)
Number of subjects: 300
Study 29976078 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg of both probiotics (MS+ SS)
Number of subjects: 300
Study 29976078 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g/kg oxytetracycline antibiotic (OX)
Number of subjects: 300
Study 29976078 — intervention group
Group type: COMPARATOR
Intervention: basal diet (negative control)
Number of subjects: 300
Study 27855663 — intervention group
Group type: EXPERIMENTAL
Intervention: Jom Mama intervention
Number of subjects: 0
Study 24123482 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 209
Study 22631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut-enriched diet (walnuts, hazelnuts, almonds) for 12 weeks
Number of subjects: 0
Study 22631214 — intervention group
Group type: COMPARATOR
Intervention: Nut-free control diet
Number of subjects: 0
Study 20980654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleurone-rich cereal products (27 g/d aleurone)
Number of subjects: 79
Study 16442463 — intervention group
Group type: EXPERIMENTAL
Intervention: Early psychosocial intervention starting within 4 months after surgery
Number of subjects: 67
Study 16442463 — intervention group
Group type: COMPARATOR
Intervention: Delayed psychosocial intervention starting at least 3 months later
Number of subjects: 67
Study 16442463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and delayed interventions
Number of subjects: 67
Study 15304189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ascorbic acid cream
Number of subjects: 16
Study 15304189 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 16
Study 12789117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 120
Study 12789117 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 120
Study 9234823 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8300
Study 9234823 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (Control)
Number of subjects: 8300
Study 8507449 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (100 mg/day, orally for 1 month)
Number of subjects: 15
Study 8507449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8507449 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 15
Study 3431029 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyenylphosphatidylcholine (10 g per day)
Number of subjects: 8
Study 3431029 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (7 g per day)
Number of subjects: 8
Study 3431029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 8
Study 28570305 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) distraction therapy
Number of subjects: 18
Study 28570305 — intervention group
Group type: COMPARATOR
Intervention: No Immersive Virtual Reality (no IVR)
Number of subjects: 18
Study 26581246 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV) plus best supportive care (BSC)
Number of subjects: 80
Study 26581246 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 80
Study 24274798 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Helping (EH)
Number of subjects: 0
Study 24274798 — intervention group
Group type: COMPARATOR
Intervention: Neutral Writing (NW)
Number of subjects: 0
Study 24274798 — intervention group
Group type: COMPARATOR
Intervention: Peer Helping (PH)
Number of subjects: 0
Study 24274798 — intervention group
Group type: COMPARATOR
Intervention: Expressive Writing (EW)
Number of subjects: 0
Study 22362846 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 220
Study 22362846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 20378181 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz stimulation, 10 sessions, 10,000 stimuli over left dorsolateral prefrontal cortex at 110% of motor threshold)
Number of subjects: 35
Study 20378181 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz stimulation)
Number of subjects: 35
Study 20378181 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 35
Study 17909750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.5 mg)
Number of subjects: 32
Study 17909750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15991021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 12738499 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 48
Study 11710653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (400 mg per day of G115)
Number of subjects: 24
Study 11710653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9024299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium phosphate supplementation
Number of subjects: 11
Study 9024299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7984562 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytic diagnosticum with BCG tuberculin
Number of subjects: 0
Study 7984562 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially designed diagnostic preparations made of TB and BCG vaccine strain tuberculin
Number of subjects: 0
Study 2880497 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocking drugs
Number of subjects: 88
Study 2880497 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blocking drugs)
Number of subjects: 88
Study 2880497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 88
Study 2880497 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline recording)
Number of subjects: 88
Study 29247383 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg
Number of subjects: 466
Study 29247383 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based doublet chemotherapy
Number of subjects: 466
Study 27938361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of spa therapy, exercise, and self-management workshops for 6 days
Number of subjects: 0
Study 27938361 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25535778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing composite restorations
Number of subjects: 20
Study 25535778 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 25535778 — intervention group
Group type: COMPARATOR
Intervention: Positive control (composites with Alfa values for marginal adaptation)
Number of subjects: 20
Study 25535778 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including sealing and no treatment)
Number of subjects: 20
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall radiotherapy (RT)
Number of subjects: 3732
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 3732
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after conservative breast surgery (PBRT)
Number of subjects: 3732
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (PRT)
Number of subjects: 3732
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: PMRT in stage III disease
Number of subjects: 3732
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: PBRT in node-positive stage II disease
Number of subjects: 3732
Study 23103364 — intervention group
Group type: EXPERIMENTAL
Intervention: PBRT in patients treated by breast conservative surgery
Number of subjects: 3732
Study 21431625 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 203
Study 21431625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 203
Study 21431625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 203
Study 21431625 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 203
Study 17622255 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zn/day
Number of subjects: 387
Study 17622255 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn/day
Number of subjects: 387
Study 17622255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 17200730 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drugs including 5‐Methyltetrahydrofolate, (R)‐flurbiprofen, Ad5CMV‐p53, adalimumab, alefacept, alemtuzumab, Alequel, alicaforsen sodium, almotriptan, anakinra, aprepitant, aripiprazole, armodafinil, Bevacizumab, bortezomib, bosentan, Canfosfamide hydrochloride, ciclesonide, clofarabine, Cypher, Darbepoetin alfa, diclofenac potassium, drotrecogin alfa (activated), duloxetine hydrochloride, Eel calcitonin, eletriptan, eplerenone, everolimus, ezetimibe, Frovatriptan, Gefitinib, γ‐hydroxybutyrate sodium, HKI‐272, HYB‐165, Ibutamoren mesylate, imatinib mesylate, interleukin‐21, ixabepilone, KRN‐951, L‐Arginine hydrochloride, levodopal carbidopa/entacapone, Micafungin sodium, motexafin gadolinium, mycophenolic acid sodium salt, Nesiritide, Peginterferon alfa‐2a, pitavastatin calcium, pralatrexate, pregabalin, pVAX/L523S‐Ad.L523S, Rasagiline mesylate, recombinant human nerve growth factor, regadenoson, rF‐PSA, rimonabant, rizatriptan, rofecoxib, rosuvastatin calcium, rV‐B7.1, rV‐PSA, Sipuleucel‐T, sirolimus‐eluting stent, solifenacin succinate, sorafenib, sunitinib malate, Talactoferrin alfa, Taxus, tegaserod maleate, teriparatide, tipifarnib, Valdecoxib, vandetanib, vatalanib succinate, WT1‐peptide vaccine, Xaliproden hydrochloride
Number of subjects: 0
Study 13129416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tegafur plus uracil (UFT) plus folinic acid
Number of subjects: 1396
Study 13129416 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluorouracil (FU) plus oral folinic acid (leucovorin)
Number of subjects: 1396
Study 10632648 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. (RBCCT group)
Number of subjects: 80
Study 10632648 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. (RBCCA group)
Number of subjects: 80
Study 10632648 — intervention group
Group type: COMPARATOR
Intervention: RBCCT group
Number of subjects: 80
Study 8619505 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled exposure to carbon monoxide at sea level
Number of subjects: 10
Study 8619505 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled exposure to carbon monoxide at high altitude
Number of subjects: 10
Study 8619505 — intervention group
Group type: COMPARATOR
Intervention: Inhaled exposure to clean air at sea level
Number of subjects: 10
Study 8619505 — intervention group
Group type: COMPARATOR
Intervention: Inhaled exposure to clean air at high altitude
Number of subjects: 10
Study 1534547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline/metronidazole (n = 67)
Number of subjects: 110
Study 1534547 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin (n = 22)
Number of subjects: 110
Study 1534547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/metronidazole (n = 21)
Number of subjects: 110
Study 1534547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline/metronidazole with balneotherapy (n = 34)
Number of subjects: 110
Study 1534547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balneotherapy, n = 33)
Number of subjects: 110
Study 6696214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 1% in air
Number of subjects: 20
Study 6696214 — intervention group
Group type: COMPARATOR
Intervention: Entonox (50% nitrous oxide in oxygen)
Number of subjects: 20
Study 30456568 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft (group A)
Number of subjects: 40
Study 30456568 — intervention group
Group type: COMPARATOR
Intervention: No bone void filler (group B)
Number of subjects: 40
Study 28855223 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (low in fat and high in protein, low-fat dairy, and fruits and vegetables) with high sodium (150 nmol or 3450 mg)
Number of subjects: 119
Study 28855223 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with medium sodium (100 nmol or 2300 mg)
Number of subjects: 119
Study 28855223 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with low sodium (50 nmol or 1150 mg)
Number of subjects: 119
Study 28855223 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 119
Study 25935787 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3‐mg intravitreal ranibizumab injection therapy
Number of subjects: 0
Study 24284115 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ALA gel applied topically for 1h incubation followed by LED light irradiation at 633 nm, 96-120 J/cm² for 3-4 sessions
Number of subjects: 397
Study 21885731 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/low-fiber diet
Number of subjects: 98
Study 21885731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/high-fiber diet
Number of subjects: 98
Study 21885731 — intervention group
Group type: COMPARATOR
Intervention: Control (enterotype identity)
Number of subjects: 98
Study 19074355 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (4 weekly sessions)
Number of subjects: 23
Study 19074355 — intervention group
Group type: COMPARATOR
Intervention: Quiet-time control (4 weekly sessions)
Number of subjects: 23
Study 16917914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen fragments (FF) isolated from uremic plasma
Number of subjects: 0
Study 16917914 — intervention group
Group type: COMPARATOR
Intervention: Normal plasma
Number of subjects: 0
Study 16917914 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic plasma before HD
Number of subjects: 0
Study 16917914 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic plasma after HD
Number of subjects: 0
Study 14743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of intravenous inotropes
Number of subjects: 73
Study 11319593 — intervention group
Group type: COMPARATOR
Intervention: No VOD prophylaxis
Number of subjects: 462
Study 11319593 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (Hep)
Number of subjects: 462
Study 11319593 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin + Prostaglandin E1 (Hep + PGE1)
Number of subjects: 462
Study 11319593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 462
Study 9345174 — intervention group
Group type: COMPARATOR
Intervention: Control (alphabetical list of drugs)
Number of subjects: 50
Study 9345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited support (list of preferred drugs)
Number of subjects: 50
Study 9345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Full support (the same list with explanations available for suggestions)
Number of subjects: 50
Study 9345174 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 9345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited support
Number of subjects: 50
Study 9345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Full support
Number of subjects: 50
Study 8084119 — intervention group
Group type: EXPERIMENTAL
Intervention: Erinit and allopurinol in conventional therapeutical doses
Number of subjects: 60
Study 8084119 — intervention group
Group type: COMPARATOR
Intervention: Erinit
Number of subjects: 60
Study 3318977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level ultrasound
Number of subjects: 40
Study 3318977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30732199 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia Wei Niu Bang Zi granule (NBZG)
Number of subjects: 120
Study 30732199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27306372 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg roflumilast
Number of subjects: 36
Study 27306372 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375 mg roflumilast
Number of subjects: 36
Study 27306372 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg roflumilast
Number of subjects: 36
Study 27306372 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 0.375 mg roflumilast
Number of subjects: 36